3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

The biotech sector witnessed a see-saw performance in 2024. Though the year started on a positive note, those gains were erased in the second half due to disappointing third-quarter results, guidance cuts, pipeline setbacks and the appointment of vaccine skeptic Robert F. Kennedy Jr. as the head of Health and Human Services.Despite these setbacks, the sector continued to attract investors’ attention due to demand for innovative medicines, especially in areas with great commercial potential, like obesity, im ...